Read original article on New African UK-based pharmaceutical company Stablepharma is preparing for a pivotal Phase 2b clinical trial of ‘SPVX02’, its thermostable version of an existing tetanus-diphtheria vaccine, following the success of a Phase 1 clinical trial. Unlike conventional vaccines which become unusable after a few hours or days out of the fridge, ‘SPVX02’ […]
Read More
Read original article on BMJ.com A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health. Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict. About half […]
Read More
Read original article on bbc.co.uk Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too […]
Read More Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand London, UK – June 15, 2026 Stablepharma Limited, specialists in thermostable formulations, today announced the signing of a Letter of Intent (LOI) with AFT Pharmaceuticals (NZX: AFT; ASX: AFP) regarding the proposed distribution of SPVX02, their lead fridge-free […]
Read More
London, UK – 15 January 2026 – Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation […]
Read More London, UK – 03 November 2025 – Stablepharma announced the database lock of its Phase 1 clinical trial of the world’s first, fridge-free, tetanus-diphtheria vaccine, SPVX02, which began recruitment in April this year. The trial evaluated the safety, tolerability and immunogenicity of SPVX02 against 2 comparator vaccines and enrolled 60 healthy participants at 2 UK […]
Read More
click here to read full article
Read More
Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility. Stablepharma’s pioneering science has […]
Read More
Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO & Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria. Ozgur also highlights some of the global challenges associated with the cold chain and talks […]
Read More